| 发明名称 | Inhaled combination therapy | ||
| 摘要 | There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery. | ||
| 申请公布号 | US9084799(B2) | 申请公布日期 | 2015.07.21 |
| 申请号 | US201313829846 | 申请日期 | 2013.03.14 |
| 申请人 | Pulmagen Therapeutics (Synergy) Limited | 发明人 | Fox Justian Craig;Fitzgerald Mary Frances;Finch Harry |
| 分类号 | A01N45/00;A61K31/56;A61K31/58;A61K31/522;A61K31/573 | 主分类号 | A01N45/00 |
| 代理机构 | Morgan, Lewis & Bockius LLP | 代理人 | Morgan, Lewis & Bockius LLP |
| 主权项 | 1. A method for the treatment of chronic obstructive pulmonary disease (COPD), comprising administering by the inhaled route for pulmonary delivery to a human subject in need thereof a composition comprising theophylline at a dose between 0.033 and 25 mg/day and a corticosteroid selected from the group consisting of mometasone furoate and beclomethasone dipropionate. | ||
| 地址 | Buckinghamshire GB | ||